Evidence map›Paper›PMID 41680540›Full record

ArticleInflammopharmacology2026

Mechanistic insights into the anti-inflammatory effects of isocoronarin D associated with reduced PKCδ and PI3K/Akt signalling in LPS-activated macrophages.

Wanatsanan Chulrik, Rungruedee Kimseng, Chutima Jansakun, Ratchanaporn Chokchaisiri, Aman Tedasen, Wilanee Chunglok, Apichart Suksamrarn, Warangkana Chunglok

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanatsanan ChulrikSchool of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, 80160, Thailand.ORCID http://orcid.org/0000-0003-2804-4921
Rungruedee KimsengSanders Brown Center on Aging, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.ORCID http://orcid.org/0000-0002-2580-9477
Chutima JansakunSchool of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, 80160, Thailand.ORCID http://orcid.org/0000-0002-7892-4436
Ratchanaporn ChokchaisiriDepartment of Chemistry, School of Science, University of Phayao, Phayao, 56000, Thailand.ORCID http://orcid.org/0000-0003-4362-0050
Aman TedasenSchool of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, 80160, Thailand.ORCID http://orcid.org/0000-0002-1350-1424
Wilanee ChunglokDivision of Biological Science, Faculty of Science, Prince of Songkla University, Songkhla, 90110, Thailand.ORCID http://orcid.org/0000-0002-3552-060X
Apichart SuksamrarnDepartment of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok, 10240, Thailand.ORCID http://orcid.org/0000-0001-8919-3555
Warangkana ChunglokSchool of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, 80160, Thailand. cwarang@wu.ac.th.ORCID http://orcid.org/0000-0002-8000-6052

Funding

The Center of Excellence for Innovation in Chemistry, Ministry of Higher Education, Science, Research, and InnovationWalailak University under the New Researcher Development Scheme WU67233
6 · The paper itself

Abstract

Curcuma comosa Roxb., a Thai medicinal plant, has long been used to relieve postmenopausal symptoms and is known to exhibit anti-inflammatory properties. Isocoronarin D, a labdane diterpene and the main bioactive compound in the aerial parts of C. comosa, has previously been reported to induce foetal haemoglobin synthesis. However, its anti-inflammatory activity, predicted molecular targets, pharmacokinetic characteristics, and toxicity remain insufficiently characterised. Therefore, this study integrates in silico predictions of its molecular targets, pharmacokinetic behaviour and toxicity with in vitro validation of its anti-inflammatory effects and underlying mechanisms to address these knowledge gaps. Initially, network pharmacology analysis identified protein kinase Cδ (PKCδ), phosphoinositide 3-kinase (PI3K), and cyclooxygenase-2 (COX-2) as inflammation-related targets computationally associated with isocoronarin D. These predicted targets were subsequently validated in vitro, where isocoronarin D significantly reduced the production of inflammatory mediators, including inducible nitric oxide synthase (iNOS), COX-2, tumour necrosis factor-α, interleukin (IL)-1β, and IL-6, in lipopolysaccharide (LPS)-activated RAW264.7 macrophages. Moreover, isocoronarin D inhibited the phosphorylation of PKCδ, PI3K, and Akt, indicating suppression of key inflammatory signalling pathways. The observed inhibition of these inflammatory proteins, together with the predicted interactions revealed by molecular docking, supports a mechanistically relevant role for these proteins as inflammatory targets of isocoronarin D. In addition, in silico SwissADME, pkCSM, and GUSAR analyses suggested drug-like characteristics, favourable pharmacokinetic properties, and a non-toxic safety profile. Collectively, these findings indicate that isocoronarin D exerts multi-target anti-inflammatory activity and warrants further in vivo investigation to better elucidate its therapeutic relevance in inflammation-related diseases.

Indexed as

Anti-Inflammatory AgentsDiterpenesMacrophagesProtein Kinase C-deltaProto-Oncogene Proteins c-aktAnimalsCyclooxygenase 2InflammationLipopolysaccharidesMiceMolecular Docking SimulationPhosphatidylinositol 3-KinasesRAW 264.7 CellsSignal TransductionAnti-Inflammatory AgentsCyclooxygenase 2DiterpenesLipopolysaccharidesPhosphatidylinositol 3-KinasesProtein Kinase C-deltaProto-Oncogene Proteins c-aktCurcuma comosa Roxb.Cyclooxygenase-2Isocoronarin DPhosphoinositide 3-kinaseProtein kinase Cδ

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.